Literature DB >> 9777054

Benzodiazepine dependence and withdrawal: a review of the syndrome and its clinical management.

E Schweizer1, K Rickels.   

Abstract

The treatment of anxiety has evolved through various phases. Currently, there is a growing recognition that anxiety disorders are frequently chronic and/or recurrent. There is also less optimism than a decade ago that benzodiazepines will be replaced by alternative agents that are not active at the benzodiazepine receptor. Consequently, the understanding and management of benzodiazepine dependence and withdrawal continue to be of some clinical importance. This article briefly reviews the withdrawal syndrome and the pharmacological and patient variables that contribute to it. It then summarizes the various approaches to managing benzodiazepine dependence and withdrawal.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9777054     DOI: 10.1111/j.1600-0447.1998.tb05973.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand Suppl        ISSN: 0065-1591


  24 in total

1.  Benzodiazepine Use and Risk of Developing Alzheimer's Disease: A Case-Control Study Based on Swiss Claims Data.

Authors:  Fabienne A Biétry; Alena M Pfeil; Oliver Reich; Matthias Schwenkglenks; Christoph R Meier
Journal:  CNS Drugs       Date:  2017-03       Impact factor: 5.749

Review 2.  Comorbidity of depression and anxiety in the elderly.

Authors:  Eric J Lenze
Journal:  Curr Psychiatry Rep       Date:  2003-05       Impact factor: 5.285

Review 3.  Can cannabis be considered a substitute medication for alcohol?

Authors:  Meenakshi Sabina Subbaraman
Journal:  Alcohol Alcohol       Date:  2014-01-08       Impact factor: 2.826

4.  The non-benzodiazepine anxiolytic drug etifoxine causes a rapid, receptor-independent stimulation of neurosteroid biosynthesis.

Authors:  Jean Luc do Rego; David Vaudry; Hubert Vaudry
Journal:  PLoS One       Date:  2015-03-18       Impact factor: 3.240

5.  Sex-related elevation in cortisol during chronic treatment with alprazolam associated with enhanced cognitive performance.

Authors:  Nunzio Pomara; Lisa M Willoughby; James C Ritchie; John J Sidtis; David J Greenblatt; Charles B Nemeroff
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

6.  Drug dependence associated with triptans and ergot derivatives: a case/non-case study.

Authors:  Frédérique Beau-Salinas; Annie Pierre Jonville-Béra; Haware Cissoko; Lamiae Bensouda-Grimaldi; Elisabeth Autret-Leca
Journal:  Eur J Clin Pharmacol       Date:  2009-12-19       Impact factor: 2.953

7.  Withdrawal from long-term benzodiazepine use: randomised trial in family practice.

Authors:  Catalina Vicens; Francisca Fiol; Joan Llobera; Francisco Campoamor; Catalina Mateu; Santiago Alegret; Isabel Socías
Journal:  Br J Gen Pract       Date:  2006-12       Impact factor: 5.386

8.  Benzodiazepines and adequacy of initial antidepressant treatment for depression.

Authors:  Paul N Pfeiffer; Dara Ganoczy; Kara Zivin; Marcia Valenstein
Journal:  J Clin Psychopharmacol       Date:  2011-06       Impact factor: 3.153

Review 9.  Withdrawing Benzodiazepines in Patients With Anxiety Disorders.

Authors:  Malcolm Lader; Andri Kyriacou
Journal:  Curr Psychiatry Rep       Date:  2016-01       Impact factor: 5.285

Review 10.  Benzodiazepine dependence and its treatment with low dose flumazenil.

Authors:  Sean David Hood; Amanda Norman; Dana Adelle Hince; Jan Krzysztof Melichar; Gary Kenneth Hulse
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.